記住我
Upcoming catalysts for the first quarter of 2023 include approval decisions by the US FDA on lecanemab for Alzheimer disease, trofinetide for Rett syndrome and beremagene geperpavec for the treatment of dystrophic epidermolysis bullosa (DEB).
Competing InterestsThe author declares no competing interests.
留言 (0)